0435-5088008
Contact:
4008465777
×
-
About Us
News & Events
-
09-06Tonghua Dongbao taps into new market with its first approved oral hypoglycemic drug Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or “the Company”) received the Pharmaceutical Product Registration Certificate for sitagliptin phosphate tablets issued by the National...
-
08-24Tonghua Dongbao reports YoY increase of 24.47% in net profit for H1 2021 as profitability continues to improve On the evening of August 24, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2021 half-year report. In H1 2021...
-
07-14Tonghua Dongbao announces NMPA acceptance of its NDA application for Insulin Aspart 30 and 50 Injections Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (“Tonghua Dongbao” or the “Company”) received the notification of acceptance from the National Medical Products Administration (NMPA) on the NDA application...
-
06-30Tonghua Dongbao introduces two novel drugs to its endocrine product portfolio On June 30, 2021, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao, introduced two novel gout (hyperuricemia) drugs - THDB130/THDB131...
-
06-28Tonghua Dongbao gets the nod for clinical trials on world’s first triple SGLT1/SGLT2/DPP4 inhibitor Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”), received the notice...
-
06-28Tonghua Dongbao wins the Best Public Service Award in the 10th Chinese Listed Companies Forum On June 27, Tonghua Dongbao was announced as the winner of the Best Public Service Award in the 10th Chinese Listed Companies Forum.The Forum was co-sponsored by the Shanghai Committee of China...